Abstract: The present invention provides a photoimageable composition comprising a polyamideimide resin, an aprotic solvent, and one or more nitrogen containing ethylenically unsaturated monomers. By addition of the nitrogen containing ethylenically unsaturated monomer, UV curable acrylates can be added to the composition, and the composition is stable. The compositions of the present invention can produce high resolution images that are flexible, hard, and have excellent resistance.

Abstract: Disclosed is a triazine ring-containing hyperbranched polymer containing a repeating unit structure represented by the expression (1). By this means, it is possible to achieve a triazine ring-containing polymer which, alone, has high heat resistance, high transparency, high refractive index, high light resistance, high solubility, low volume shrinkage without adding metal oxides; and also a membrane-forming composition containing the same. In the formula, R and R? represent independently a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, or an aralkyl group, and A represents an alkylene group optionally having a branched or alicyclic structure of 1 to 20 carbon atoms.

Abstract: A new metallo-?-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of ?-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-?-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of ?-lactam antibiotics against metallo-?-lactamase producing bacteria by combining the compound of the general formula (I) with ?-lactam antibiotics.

Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

Abstract: There are provided a novel diarylamine compound represented by the following formula (I), (II) or (III), which has at least one signal attributable to the hydrogen of the N—H moiety at 8.30 ppm to 9.00 ppm when a deuterated dimethyl sulfoxide solution of the diarylamine compound is analyzed by 1H-NMR; and an aging inhibitor, a polymer composition, a crosslinked rubber product and a molded article thereof, and a method of producing a diarylamine compound. In the formulas, A1 to A6 each represent an aromatic group which may have a substituent; A represents an aromatic group or a cyclic aliphatic group, which may both have a substituent; L represents 1 or 2; and n represents 0 or 1.

Abstract: Disclosed are novel cross-linkable end-cappers for oligo- and polyamides. End-capped oligo- and polyamides comprising such an end-capper may be cured at a lower temperature compared to oligo- and polyamides end-capped with PEPA.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: Disclosed are novel cross-linkable end-cappers for oligo- and polyamides. End-capped oligo- and polyamides comprising such an end-capper may be cured at a lower temperature compared to oligo- and polyamides end-capped with PEPA.

Abstract: This invention relates to polymerizable ultraviolet light absorbers and yellow colorants and their use in ophthalmic lenses. In particular, this invention relates to polymerizable ultraviolet light absorbing methane compounds and yellow compounds of the methine and anthraquinone classes that block ultraviolet light and/or violet-blue light transmission through ophthalmic lenses.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: A benzoindole-based compound represented by Formula 1 below, a dye including the benzoindole-based compound, and a dye-sensitized solar cell including the dye: is prepared at a low cost, has a high molar absorption coefficient, and high photoelectron conversion efficiency, as compared to a conventional ruthenium dye. The benzoindole-based dye is an organic dye including an N-aryl electron donor and an acidic functional group an electron acceptor.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: The present invention relates to compounds that are suitable for treatment of disease states and influence cellular vesicular systems, especially the formation and/or function of lipid droplets, said compound having the general formula I (I) wherein X are each independently hydrogen, halogen, —C1-20-alkyl, —C2-20-alkenyl, —C2-20-alkinyl, —C5-6-cykloalkyl, aryl, aralkyl, adamantyl, heterocyclic, hydroxyl, hydroxyalkyl, Or —N—(R1, R2) group; n is 0, 1, 2, 3, or 4; R1 and R2 may each be independently hydrogen, straight or branching alkyl, cyclo-alkyl, aryl, aralkyl, heterocyclic group, wherein each is un-substituted or halogen substituted; or R1 and R2 together with the nitrogen in between them form a 5 or 6 member ring; A is a single bond, —O—, —S—, —CH2-, or —NH—; Y is O or S; Z is O or S; R? and R? are each independently methyl, ethyl, isopropyl, isobuthyl, sec-butyl or terc-butyl; with the restriction that: X(n) cannot all be fluorine, and A be a single bond, and Y, as well as Z be O, and R?, as well as R? b

Abstract: The present disclosure provides a process for the mono-reduction of one or more imide moieties in a compound comprising contacting the compound with hydrogen gas and a catalyst comprising a transition metal hydride in the presence of a base, under conditions for the mono-reduction of the one or more imide moieties to form a compound comprising one or more hydroxy amides.

Abstract: There are provided a novel diarylamine compound represented by the following formula (I), (II) or (III), which has at least one signal attributable to the hydrogen of the N—H moiety at 8.30 ppm to 9.00 ppm when a deuterated dimethyl sulfoxide solution of the diarylamine compound is analyzed by 1H-NMR; and an aging inhibitor, a polymer composition, a crosslinked rubber product and a molded article thereof, and a method of producing a diarylamine compound. In the formulas, A1 to A6 each represent an aromatic group which may have a substituent; A represents an aromatic group or a cyclic aliphatic group, which may both have a substituent; L represents 1 or 2; and n represents 0 or 1.

Abstract: A production method of a compound containing a primary, secondary, or tertiary aminomethyl aromatic ring of the present invention includes: using a fluoroboron compound or a dimer thereof, or solvates thereof, which are represented by a formula (I): Ra(Rb)N—CH2—BF3M??(I) as an aminomethylating agent for an aromatic ring; and reacting the aminomethylating agent with an aromatic ring-containing compound, which can react with the aminomethylating agent, under the presence of a metal catalyst such as a palladium compound so as to perform the direct aminomethylation of the aromatic ring.

Abstract: Pentafluorosulfanyl-benzenes according to Formula (I): a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and arthropodicides.

Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof

Abstract: A benzoindole-based compound represented by Formula 1 below, a dye including the benzoindole-based compound, and a dye-sensitized solar cell including the dye: is prepared at a low cost, has a high molar absorption coefficient, and high photoelectron conversion efficiency, as compared to a conventional ruthenium dye. The benzoindole-based dye is an organic dye including an N-aryl electron donor and an acidic functional group an electron acceptor.

Abstract: The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases.

Abstract: A compound of formula (1) or a pharmaceutically acceptable derivative thereof, where R1, R2, R3, R4, R5, X and Y are as defined in the specification; corresponding processes for preparing; pharmaceutical compositions comprising; and medicinal uses of such compounds.

Abstract: Novel methods are provided to prevent blindness associated with diabetic macular edema by administration of a phenylphthalimide analog. Additionally, sustainability of the effect of administration of the phenylphthalimide analog is improved via encapsulation with poly(lactic-co-glycolic acid) nanoparticles. Finally, a novel method for synthesizing (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione is disclosed.

Abstract: The invention provides an acetylene compound represented by the following Formula (1), which is useful as a raw material for a polymer achieving high thermal resistance; wherein, in Formula (1), the encircled Ar represents an aryl group or a heteroaryl group; X represents a divalent linking group; R, R? and R1 each independently represent a hydrogen atom, a hydrocarbon group or a heterocyclic group; R2 represents a hydrogen atom or a substituent substitutable on a benzene ring; A represents a hydrocarbon group or a heterocyclic group; Q represents a hydrogen atom, a hydrocarbon group, or a metal element capable of forming a monovalent metal salt; a represents an integer from 0 or more; b, m and n each independently represent an integer of 1 or more; when n, m and b are 1 at the same time, X is not —(C?O)O—; and when n is 2, and both m and b are 1, X is not —O—.

Abstract: The present invention relates to compounds that are suitable for treatment of disease states and influence cellular vesicular systems, especially the formation and/or function of lipid droplets, said compound having the general formula I (I) wherein X are each independently hydrogen, halogen, —C1-20-alkyl, —C2-20-alkenyl, —C2-20-alkinyl, —C5-6-cykloalkyl, aryl, aralkyl, adamantyl, heterocyclic, hydroxyl, hydroxyalkyl, Or —N—(R1, R2) group; n is 0, 1, 2, 3, or 4; R1 and R2 may each be independently hydrogen, straight or branching alkyl, cyclo-alkyl, aryl, aralkyl, heterocyclic group, wherein each is un-substituted or halogen substituted; or R1 and R2 together with the nitrogen in between them form a 5 or 6 member ring; A is a single bond, —O—, —S—, —CH2-, or —NH—; Y is O or S; Z is O or S; R? and R? are each independently methyl, ethyl, isopropyl, isobuthyl, sec-butyl or terc-butyl; with the restriction that: X(n) cannot all be fluorine, and A be a single bond, and Y, as well as Z be O, and R?, as well as R? b

Abstract: A material for use in flexible printed wiring board having high reliability and allowing for processing fine wiring includes a compound represented by the following general formula (I): wherein one of X and Y represents O and the other represents NAr2R2, and R1, R2, Ar1, and Ar2 are as defined in the specification, and a resin composition comprising the compound as a reactive monomer.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The present invention provides a process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane, which includes reacting (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-hydroxymethylcyclopropane with an orthoester and a brønsted acid, and reacting the reaction product with a phthalimidating agent; and a process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcyclopropane hydrochloride through the above process.

Abstract: A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed.

Abstract: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the ?4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which ?4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Abstract: Melt blended compositions, comprising up to 20 wt % of an optional additive, and 80-100 wt % of a copolycarbonate having a Tg of 200° C. or more of (1) wherein the mole ratio of x:y is 35:65 to 90:10, R1 is derived from a dihydroxy compound (2) wherein R3 and R5 are each independently a halogen or a C1-6 alkyl group, R4 is a C1-6 alkyl, phenyl, or phenyl substituted with up to five halogens or C1-6 alkyl groups, and each c is independently 0 to 4; R2 is derived from a dihydroxy compound (6): wherein Ra and Rb are each independently a halogen atom or a monovalent C1-6 alkyl group; p and q are each independently integers of 0 to 4; and Xa is a divalent group; and 95 to 5 wt % of a polycarbonate having a Tg of less than 200° C. of formula (9) wherein R9 derived from a dihydroxy compound of formula (6); and 0.001 to 0.1 wt % of a transesterification catalyst.

Abstract: Thalidomide analog compounds having a general structure are described. R1 is selected from a group comprising of hydroxy, hydrogen, and amino. Also described is a method for treating vascular abnormalities, such as neovascularization and vascular leakage. A therapeutically effective amount of a composition containing the thalidomide analog compound is administered to a patient. The composition may further include agents, such as solubilizing agents, inert fillers, diluents, excipients, or flavoring agents.

Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C?O, C?S, S?O, SO2, S, O, (CR6R7)n, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.

Abstract: Disclosed is a flame retardant crosslink agent free of halogen and phosphorous. The crosslink agent can be applied in epoxy resin composition, such that the composition achieves V0 under UL-94 standard after curing. The crosslink agent, a novolac structure modified by nitrogen-containing and/or silicon containing compound, may collocate with inorganic powder, such that the thermal cured epoxy resin composition contains thermal retardancy, low expansion, low water uptake, and high glass transfer temperature properties. The epoxy resin composition including the crosslink agent of the invention can be applied in a prepreg used in copper clad laminates or printed circuit plates.

Abstract: A polymer comprising structural units derived from a polycyclic dihydroxy compound of Formula (I) wherein R1, R2 and R3 are independently at each occurrence selected from the group consisting of a cyano functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons, and an aromatic functionality having 6 to 10 carbons; wherein each occurrence of “n”, “m”, and “p” independently has a value of 0, 1, 2, 3, or 4; and wherein the polymer is substantially linear.

Abstract: A method for increasing a mean particle size of a 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine is provided. The method comprises forming a mixture comprising a feedstream of the 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine, and a solvent composition comprising an organic solvent and water, wherein the organic solvent is capable of at least partially dissolving the 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine and forming an adduct with the 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine. Then the mixture is heated at a temperature and for a time effective to decompose the adduct and form a 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine product having a mean particle size greater than 5 microns. The 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidines with increased particle size are useful for producing polymers.

Abstract: Pentafluorosulfanyl-benzenes according to Formula (I): a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and arthropodicides.

Abstract: The invention concerns the use of indoline derivatives of formula (I): in which R1, R2, R3, R4 and R5 independently of one another represent hydrogen or C1-4 alkyl groups, or R4 and R5 together with the oxygen atoms to which they are attached represent a C1-4 alkylenedioxy group, or of salts of such indoline derivatives, as additives to hair dyeing agents of the direct dyeing or primary intermediate/secondary intermediate type, thus producing hair dyeing with excellent color fastness characteristics.

Abstract: Novel imides are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is (R)-2-Phthalimido-3-(3?,4?-dimethoxyphenyl)propane.

Abstract: Reactor membranes for used in oxidation reactions of hydrocarbons involving oxygen comprising a selective oxidation catalyst on a mixed conducting, oxide ion selective ceramic membrane of the composition (Sr1-xCax)1-yAyMn1-zBzO3-&dgr;, where A is Ba, Pb, Na, K, Y, an element of the lanthanide group or a combination thereof, B is Mg, Al, Ga, In, Sn, an element of the 3d or 4d period or a combination thereof, x is from 0.2 to 0.8, y is from 0 to 0.4, z is from 0 to 0.6, and &dgr; is a number, dependent on x, y and z, that renders the composition charge neutral.

Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: This invention relates to phthalimido derivatives of the formula wherein X is —N═ or —CH═, and R1 to R4 and m are as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to pharmaceutical compositions containing these compounds, a method of treating a disease by administering a therapeutically effective amount of at least one of these compounds, and a process for their preparation for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial.

Abstract: A method for the manufacture of halophthalic acid by liquid phase oxidation of halo-ortho-xylene is disclosed. The halophthalic acid may be dehydrated to form halophthalic anhydride which is useful in the synthesis of polyetherimide.

Abstract: A method for the manufacture of chlorophthalic acid by liquid phase oxidation of chloro-ortho-xylene is disclosed. The chlorophthalic acid may be dehydrated to form chlorophthalic anhydride which is useful in the synthesis of polyetherimide.

Abstract: A method for the manufacture of halophthalic acid by liquid phase oxidation of halo-ortho-xylene is disclosed. The halophthalic acid may be dehydrated to form halophthalic anhydride which is useful in the synthesis of polyetherimide.

Abstract: A self-polymerizable AB2 monomer of the formula The resulting AB2 monomer can be polymerized to afford high molecular, low viscosity hyperbranched ether-ketone-imide polymer having repeating units with hydroxyl endgroups.

Abstract: Novel herbicidal and defoliant substituted aniline derived compounds represented by general structure (I) 1

Abstract: The present invention relates to polyamide-imides having head-to-tail backbone and more particularly, to polyamide-imimdes having head-to-tail ragularity to provide excellent heat and chemical resistance, physical and mechanical properties, processability, and gas permeability and selectivity.

Abstract: Novel imides are inhibitors of tumor necrosis factor &agr; and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 2-Phthalimido-3-(3′,4′-dimethoxyphenyl)propane.

Abstract: A phthalimide represented by general formula (I): wherein L represents L-1 or L-2: (wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, etc.); A represents an oxygen atom, a sulfur atom or —NR5— (wherein R5 is a hydrogen atom, an alkyl group, an alkenyl group, etc.); R represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a phenyl group, etc.; X represents a halogen atom; Y represents a hydrogen atom or a halogen atom; and Z represents a hydrogen atom, an alkyl group, a haloalkyl group or a halogen atom. The compound exhibits excellent herbicidal effects with high selectivity.